Checkpoint inhibition for early-stage hormone receptor-positive breast cancer

  • Published on 07/04/2024
  •  Reading time: 4 min.

Ilana Schlam a,b , Chiara Corti c,d,e,f,g , Sarah Sammons c,d,e , Elizabeth A. Mittendorf d,e,h & Sara M. Tolaney c,d,e,*

a Department of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA
b School of Medicine, Tufts University, Boston, MA, USA
c Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
d Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA
e Harvard Medical School, Boston, MA, USA
f Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy
g Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy
h Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA

CONTACT Sara M. Tolaney mailto:sara_tolaney@dfci.harvard.edu Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA

ContentGeneMD

To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Oncology

Receive our newsletter to stay up to date with the latest news in Oncology